FDA’s settlement of the Vascepa (icosapent ethyl) off-label marketing case is another important development in pharmaceutical and medical device industry First Amendment disputes that experts say may put additional pressure on FDA to revise its approach to off-label promotion.
The settlement with drug manufacturer Amarin Corp. PLC includes an optional preclearance provision for future communications about unapproved uses...